VTRS · News · 20260807N
Acquisition / Partnership / Divestiture
Viatris Inc · 2026-08-07 · Importance 34 · Surprise 42 · In source text
Viatris agreed to sell the global rights to Tyrvaya, its varenicline solution nasal spray for dry eye disease, to Harrow Inc. The transaction includes $30 million of upfront cash and up to $70 million in contingent milestone payments, for total potential consideration of $100 million. The deal is expected to close in the second half of 2026. Viatris is using the divestiture to focus capital and operating resources on complex generics, transdermal products, and growth in Greater China.
Key facts
- Viatris agreed to sell Tyrvaya to Harrow Inc. for up to $100 million, consisting of $30 million upfront cash and up to $70 million in contingent milestone payments. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | — | Viatris agreed to sell Tyrvaya to Harrow Inc. for up to $100 million, consisting of $30 million upfront cash and up to $70 million in… |
| assets | positive | contingent | — | Viatris agreed to sell Tyrvaya to Harrow Inc. for up to $100 million, consisting of $30 million upfront cash and up to $70 million in… |